Paul G. Richardson, MD, on Treatment Strategies for Newly Diagnosed Multiple Myeloma

Posted: Tuesday, December 15, 2020

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, reviews pivotal studies presented at the 2020 American Society of Hematology Annual Meeting & Exposition and discusses integrating early vs late transplant with drugs such as daratumumab, carfilzomib, and anti-CD38 monoclonal antibodies into an overall treatment strategy for patients with newly diagnosed multiple myeloma.